ArticleBriefings in bioinformatics2025
ProDualNet: dual-target protein sequence design method based on protein language model and structure model.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How far can you go? Extrapolating values of catalytic activity from known protein landscapes in natural and directed evolution.Chemical Society reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Proteins typically interact with multiple partners to regulate biological processes, and peptide drugs targeting multiple receptors have shown strong therapeutic potential, emphasizing the need for multi-target strategies in protein design. However, most current protein sequence design methods focus on interactions with a single receptor, often neglecting the complexity of designing proteins that can bind to two distinct receptors. We introduced Protein Dual-Target Design Network (ProDualNet), a structure-based sequence design method that integrates sequence-structure information from two receptors to design dual-target protein sequences. ProDualNet used a heterogeneous graph network for pretraining and combines noise-augmented single-target data with real dual-target data for fine-tuning. This approach addressed the challenge of limited dual-target protein experimental structures. The efficacy of ProDualNet has been validated across multiple test sets, demonstrating better recovery and success rates compared to other multi-state design methods. In silico evaluation of cases like dual-target allosteric binding and non-overlapping interface binding highlights its potential for designing dual-target binding proteins. Data and code are available at https://github.com/chengliu97/ProDualNet.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.